Liminal BioSciences Inc. PFSCF

Primary Symbol: LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > im surprised, pretty much no spam for 2 days!

<< Previous

Bullboard Posts

Next >>

Comment by Arrakis37on Jun 03, 2020 11:41am

92 Views

Post# 31106779

RE:im surprised, pretty much no spam for 2 days!

You can't even read...

You're pathetic...

LOL

Newcamo wrote:

The geniuses have finally bought:))) Good boys! LMNL completed 100% the check points as asked by the FDA, now they will submit riplazym as detailed below, FDA already reviewed riplazym and passed conditional on those check points being set. They are set, resubmission is basically a formality. The 2 owners indeed own 85% of all shares, stay tuned:In early 2019 the Company established the following critical path towards regulatory approval for RyplazimTM in the U.S. is as follows:

1. Development and validation of new analytical assays and in-process controls (complete)
2. Finalization of PPQ protocol (complete)
3. Manufacturing of additional conformance lots (complete)
4. Fill & Finish at external Contract Manufacturing Organization (“CMO”) (complete)
5. Data analysis & preparation of required documents for FDA (in process)
6. Regulatory filing of BLA amendment documents – now likely to take place in H1 2020
7. Anticipated new PDUFA date after the acceptance of the amended BLA"
____________________________________________________________________

Anticipated Key Milestones (from corp. slides)

1H-2020Expected commercial partnership for Ryplazim™

1H-2020Expected filing of amended BLA with FDA for Ryplazim™ (priority review expected)

TV + consonance own 85% of all shares in lmnl, must be a little confident that they will make it happen;)

Newcamo (325)

May 29, 2020 - 03:34 PM

120 Reads

Post# 31089488

Day high: 15.49$.... NR: corp update june 4th..........

Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

T.LMNL |

LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at Jefferies Virtual Healthcare Conference on Thursday 4th June at 14:30.

The presentation will be webcast live on the Webcasts page of the Investors & Media section of the Company's website, or by following the link below in your web browser. An archived replay of the webcast will be available on the Company's website for at least 7 days after the live event concludes.
https://wsw.com/webcast/jeff126/pli/